Agile Therapeutics, Inc. Aktie News

Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement Until March 25, 2024

Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Women

The Company Commends House Committee on Oversight and Accountability Ranking Member Jamie Raskin for New Report on Contraception Coverage Gaps

Whether you subscribe to the idea that penny stocks are always a buy or determine your strategy based on broader market conditions, chances are that cheap stocks are on your watch list. While these sweeping market trends might not influence low-priced equities, it's important to understand what's going on in the stock market today.

PRINCETON, NJ / ACCESSWIRE / November 22, 2023 / Agile Therapeutics, Inc. (NASDAQ:AGRX), the commercial-stage women's healthcare company, posted a 122% increase in third-quarter revenue year-over-year, driven by strong demand for TwirlaⓇ (levonorgestrel and ethinyl estradiol) transdermal system, its birth control patch. The company also reiterated its target for full-year 2023 revenue of at lea...

Agile Therapeutics, Inc. (AGRX) Q3 2023 Earnings Call Transcript

Twirla Delivers Third Quarter 2023 Net Revenue of $6.7 Million, a 21% Increase from Second Quarter 2023 Company Announces It Expects to Generate Positive Cash Flow from Operations in First Quarter 2024 Gross Margin Grows to 63% in Third Quarter 2023 from 58% in Second Quarter 2023 Company Reaffirms Expected Full Year 2023 Net Revenue of At Least $25 Million Management to Host Conference Call To...

Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J.